Anthrax vaccine adsorbed

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Retrieved on: 
목요일, 1월 11, 2024
EBS, Pre-exposure prophylaxis, Radiation, Emergent, Anthrax vaccine adsorbed, Anthrax, IDIQ, Emergent BioSolutions

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

Key Points: 
  • GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
  • The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033.
  • “As a part of our mission to protect and enhance lives, Emergent is proud to continue supporting and preparing our nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax vaccine,” said Paul Williams, senior vice president, products head at Emergent.
  • “This new contract award is a testament to the importance of Emergent’s medical countermeasures portfolio, and we look forward to delivering on our commitments to the U.S. DoD.”
    Under the initial five-year IDIQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million.

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Retrieved on: 
목요일, 7월 20, 2023
Post-exposure prophylaxis, Biologics license application, Emergent BioSolutions, Partnership, Biomedical Advanced Research and Development Authority, DARPA, Office of Inspector General, U.S. Department of Health and Human Services, EBS, Human services, Public, National Institute of Allergy and Infectious Diseases, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Person, Bangladesh Technical Education Board, Government, Science, Trial of the century, Bacillus anthracis, Administration, Development, Anthrax, Administration for Strategic Preparedness and Response, AVA, NIAID, FDA, Anthrax vaccine adsorbed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, NYSE, Food, Safety, Disease, Pharmaceutical industry, Vaccine, Emergent, Adjuvant

The efficacy of CYFENDUS™ vaccine for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.

Key Points: 
  • The efficacy of CYFENDUS™ vaccine for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.
  • “The 20-year journey from early development to approval is a major milestone that attests to Emergent's scientific and technical prowess and partnering capabilities.
  • “The approval of the CYFENDUS™ vaccine demonstrates what effective public-private partnerships can achieve for national security.
  • In December 2018, CYFENDUS™ vaccine was the subject of a pre-emergency use authorization package submitted to the FDA.

Anthrax Drugs Pipeline Market Research Report 2022: Comprehensive Insights on 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
금요일, 3월 4, 2022
Health, Pharmaceutical, NDA, Infection, Emergent, Bacillus anthracis, News, Post-exposure prophylaxis, Anthrax vaccine adsorbed, Disease, Acquisition, Clinical trial, Technology, AVA, III, II, Discovery, Therapy, Vaccine, Anthrax

The publisher's, "Anthrax - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape.

Key Points: 
  • The publisher's, "Anthrax - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape.
  • 'Anthrax - Pipeline Insight, 2022' report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines.
  • The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development.

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

Retrieved on: 
일요일, 1월 9, 2022
Face, Licensure, COVID-19, Government, Therapy, Good manufacturing practice, Emergent, CDMO, Life, ACAM2000, Risk, U.S. Securities and Exchange Commission, Twitter, CHIKV, Security (finance), Contract, Biologics license application, Private Securities Litigation Reform Act, Anthrax vaccine adsorbed, LinkedIn, Marketing, FDA, Instagram, Compliance, Public health, Investment, VLP, Public expenditure, Risk management, Pharmaceutical industry

We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics.

Key Points: 
  • We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics.
  • For over 20 years, weve been at work defending people from things we hope will never happenso that were prepared, just in case they ever do.
  • We do what we do because we see the opportunity to create a better, more secure world.
  • The reader should realize that if underlying assumptions prove inaccurate or unknown risks or uncertaintiesmaterialize, actual results could differ materially from our expectations.

List Labs Announces New Anthrax Lethal Factor Detection Method

Retrieved on: 
목요일, 12월 13, 2018
Health, Biological weapons, RTT, Zoonoses, Medicine, Anthrax, Animal health, Infection, Anthrax attacks, Anthrax vaccine adsorbed

CAMPBELL, Calif., Dec. 13, 2018 /PRNewswire/ --Since the intentional release of anthrax spores leading to lethal inhalational anthrax in 2001, the need for rapid and sensitive detection of infection has been critical.

Key Points: 
  • CAMPBELL, Calif., Dec. 13, 2018 /PRNewswire/ --Since the intentional release of anthrax spores leading to lethal inhalational anthrax in 2001, the need for rapid and sensitive detection of infection has been critical.
  • This protein, anthrax lethal factor , is produced early in infection in a quantity sufficient for detection making it possible to rapidly determine that a patient is infected and to initiate therapy.
  • A reagent that specifically detects the presence of low amounts of lethal factor from anthrax infection is described.
  • This study sets a new standard for a sensitive, simple, and specific method to detect anthrax infection.